Register

Login

Vet Times logo
+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
    • Crossword
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • All Jobs
  • Your ideal job
  • Post a job
  • Career Advice
  • Students
About
Contact Us
For Advertisers
NewsClinicalJobs
Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcastsDigital EditionCrossword

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

All Jobs

Your ideal job

Post a job

Career Advice

Students

More

All More content

Videos

Podcasts

Digital Edition

Crossword


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2025

IPSO_regulated

26 May 2023

Pets at Home Vet Group revenue up 13.3% and its pre-tax profit hits £50.9 million

Overall Pets at Home company revenue, including retail division, rose 6.6% to £1.4 billion, with statutory profit before tax down from £148.7 million to £122.5 million.

author_img

Paul Imrie

Job Title



Pets at Home Vet Group revenue up 13.3% and its pre-tax profit hits £50.9 million

Image: © ipopba / Adobe Stock

Vets for Pets practices helped their owner Pets at Home’s Vet Group increase revenue 13.3% to £122.8 million in the past year.

Releasing preliminary results for the 52 weeks to 30 March 2023, Pets at Home Group said total revenue had increased 6.6% to £1.404 billion, with a lower overall statutory profit before tax of £122.5 million (£148.7 million in 2022).

However, the proportion of that to come from the vet group rose 18.3% to £50.9 million from £43.1 million a year earlier.

Joint venture partners

In its preliminary full-year results and strategy update announcement, the vet group – which has rebranded to Vets for Pets from Vets4Pets and runs as a joint-venture partnership model – was described as a “£500 million consumer revenue business”, establishing it as a top-three UK player in scale.

Average revenue per practice is up 57% to £1.1 million from £700,000 in 2019, 60% of joint venture partnerships are now described as debt free and total of £33 million was paid to partners in dividends in year to 30 March 2023.

The Pets at Home market share is up to 24 per cent, with the vet group’s share of the £2.5 billion veterinary sector now standing at 19%.

‘Record performance’

Lyssa McGowan, Pets at Home’s chief executive officer, said: “Our record performance over the past year demonstrates that our compelling pet care offer continues to resonate strongly with consumers. Through our unique blend of products, services and expert advice we were able to serve pet owners better, grow our consumer base and win more market share, building on our leading position in the UK pet care market.

“I would like to thank all of our incredible colleagues for their continued passion and dedication to our great business. It is our unique culture that sets us apart and will continue to underpin everything we do.”

And Louise Stonier, vet group chief operating officer, said: “What has become crystal clear to me is the passion and dedication of our partners and their teams, and the strength of our unique [joint venture] model. There is no question in my mind that this, together with clinical freedom at the very heart of our model, is our competitive advantage.”